ImmunityBio (IBRX) Capital Leases (2016 - 2018)

ImmunityBio (IBRX) has reported Capital Leases for 3 consecutive years, with $5.9 million the latest figure, recorded in Q4 2018.

• In Q4 2018, Capital Leases rose 241.47% year-over-year to $5.9 million; the TTM figure through Dec 2018 stood at $5.9 million (up 241.47% YoY), while the FY2018 annual figure was $5.9 million, up 241.47% from the prior year.
• Capital Leases slipped to $5.9 million in Q4 2018 per IBRX's latest filing, from $6.1 million in the prior quarter.
• Across five years, Capital Leases topped out at $6.3 million in Q2 2018 and bottomed at $1.7 million in Q1 2018.
• Historically, Capital Leases has averaged $3.2 million across 3 years, with a median of $2.0 million in 2016.
• Annual changes were most pronounced in 2017 — Capital Leases fell 24.1% — and 2018, when it surged 241.47%.
• ImmunityBio's Capital Leases stood at $2.0 million in 2016, then retreated by 14.02% to $1.7 million in 2017, then soared by 241.47% to $5.9 million in 2018.
• Business Quant data shows IBRX's Capital Leases at $5.9 million in Q4 2018, $6.1 million in Q3 2018, and $6.3 million in Q2 2018.